TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05181241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin
Description: Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin
Description: Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin
Description: Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia
Study: NCT02348840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth
Description: A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
Study: NCT03486249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetition of medical examinations performed as part of the care
Description: Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
Study: NCT01643304

Intervention type: BEHAVIORAL
Intervention: No drug
Description: No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
Study: NCT00748306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 - 100mcg
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Intervention Drug
Study: NCT02975349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib 75 milligrams (mg) orally, twice daily (BID) up to Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib 25 mg orally, once daily (QD) up to Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants received Evobrutinib 75 mg orally, QD up to Week 48

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were administered for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo were administered for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecfidera
Description: Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (48 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Following Placebo for 24 weeks, participants received Evobrutinib 25 milligram (mg) orally, once daily (QD) from Week 24 to 48 weeks.
Study: NCT06484725

Intervention type: GENETIC
Intervention: Oncotype DX assay
Description: Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.

Intervention type: GENETIC
Intervention: Oncotype DX assay
Description: Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.

Intervention type: GENETIC
Intervention: Oncotype DX assay
Description: Oncotype DX assay (Genomic Health, Inc, Redwood City, Calif) is a 21 gene panel developed to predict the risk of tumor recurrence in patients with ER-positive and human epidermal growth factor 2 (HER2)- negative breast cancer (BC); nowadays, this test represents a standard of care to guide adjuvant chemotherapy decision recommended in several guidelines. According to Oncotype DX Recurrent Score (RS)® a high RS shows a worse prognosis and predicts chemotherapy benefit in patients with ER-positive HER2-negative BC.
Study: NCT03849287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula I
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333, formula II
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330, D090
Description: Reference Drug
Study: NCT02085135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet taken once daily
Study: NCT02891252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: outpatient procedure
Study: NCT04099836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks
Study: NCT04046276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Aerobic program
Description: Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Medium Intensity Aerobic program
Description: Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
Study: NCT01339208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine diabetes intervention
Description: 3 month duration telemedicine consultation and diabetes education
Study: NCT01465373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endometrin
Description: 100 mg per vagina TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in Oil
Description: 50 mg IM injection daily
Study: NCT04494477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The IN•clued program
Description: The INclued program as previously described.
Study: NCT00806650

Intervention type: GENETIC
Intervention: gene expression analysis
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples

Intervention type: GENETIC
Intervention: protein expression analysis
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic laboratory biomarker analysis
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples

Intervention type: OTHER
Intervention: immunoenzyme technique
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Description: Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
Study: NCT00744991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
Study: NCT03170908

Intervention type: BEHAVIORAL
Intervention: Interpersonal Psychotherapy
Description: Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression

Intervention type: BEHAVIORAL
Intervention: Interpersonal Psychotherapy
Description: Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
Study: NCT00570895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2.
Study: NCT04020965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sanitation
Description: Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwashing
Description: Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits.
Study: NCT02767830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Excercise and Nutrition Program
Study: NCT04062474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Intervention with TNF-α inhibitor
Description: Epidural administration with TNF-α inhibitor
Study: NCT02910674

Intervention type: DEVICE
Group type: OTHER
Intervention: Dario Blood Glucose Monitoring System
Description: Accuracy with usability assessment
Study: NCT01879865

Intervention type: OTHER
Group type: OTHER
Intervention: Non-stimulation
Description: The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.

Intervention type: OTHER
Group type: OTHER
Intervention: Stimulation
Description: The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
Study: NCT04175444

Intervention type: DIAGNOSTIC_TEST
Intervention: VisuALL Field Analyzer
Description: Each participant will conduct a visual field test with the visuaALL headset.

Intervention type: DIAGNOSTIC_TEST
Intervention: Humphrey Field Analyzer
Description: Each participant will conduct a standard of care Humphrey Visual Field.
Study: NCT03603548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
Study: NCT03791710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous fat grafting
Description: regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Cream
Description: serial dressing with topical agents e.g Silver Sulphadiazine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: split thickness skin grafting
Description: depridment and split thickness skin grafting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: split thickness skin grafting
Description: depridment and split thickness skin grafting
Study: NCT04091659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Education
Description: Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
Study: NCT03400943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily up to 2 x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily up to 2 x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily up to 2 x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily up to 2 x 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo was administered to group B1 and B2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo was administered to group B1 and B2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo was administered to group B1 and B2.
Study: NCT01830634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theraband with strengthening and stretching exercise
Description: Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day.
Study: NCT01162746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone and intravitreal ranibizumab
Description: Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT.
Study: NCT01283178

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo intensity-modulated image-guided adaptive radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided adaptive radiation therapy
Description: Undergo intensity-modulated image-guided adaptive radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine
Description: Undergo FLT-PET scans for IMRT/IGART
Study: NCT01162746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab
Description: Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
Study: NCT00899041

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Description: 28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA)
Description: 28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
Study: NCT00769990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.